Overlapping Therapy with High-Dose Tamoxifen and CYP2D6 Inhibitors Modifies Medication Adherence in Breast Cancer Patients

被引：0
|
作者：
Markward, N. J.
Tinnirello, J.
Khalid, M.
Frueh, F. W.
Milayna, S.
Aubert, R. E.
Epstein, R. S.
机构：
[1] Medco Hlth Solut Inc, Bethesda, MD USA
[2] Medco Hlth Solut Inc, Franklin Lakes, NJ USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P4-02-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients
    Keller, Denise
    Medwid, Samantha
    Schwarz, Ute
    Legan, Robin
    Kim, Richard
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 250 - 253
  • [2] Dose adjustment of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
    不详
    PHARMACOGENOMICS, 2012, 13 (06) : 647 - 648
  • [3] Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
    Aubert, R. E.
    Stanek, E. J.
    Yao, J.
    Teagarden, J. R.
    Subar, M.
    Epstein, R. S.
    Skaar, T. C.
    Desta, Z.
    Flockhart, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [4] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Laurent Azoulay
    Sophie Dell’Aniello
    Laetitia Huiart
    Guillaume Galbaud du Fort
    Samy Suissa
    Breast Cancer Research and Treatment, 2011, 126 : 695 - 703
  • [5] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Azoulay, Laurent
    Dell'Aniello, Sophie
    Huiart, Laetitia
    du Fort, Guillaume Galbaud
    Suissa, Samy
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) : 695 - 703
  • [6] Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen
    Ferraldeschi, Roberta
    Howell, Sacha J.
    Thompson, Alastair M.
    Newman, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : E584 - E585
  • [7] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
    Martinez de Duenas, Eduardo
    Ochoa Aranda, Enrique
    Blancas Lopez-Barajas, Isabel
    Ferrer Magdalena, Teresa
    Bandres Moya, Fernando
    Chicharro Garcia, Luis Miguel
    Gomez Capilla, Jose A.
    Zafra Ceres, Mercedes
    de Haro, Tomas
    Romero Llorens, Regina
    Ferrer Albiach, Carlos
    Ferriols Lisart, Rafael
    Chover Lara, Dolores
    Lopez Rodriguez, Angela
    Munarriz Ferrandis, Javier
    Olmos Anton, Santiago
    BREAST, 2014, 23 (04): : 400 - 406
  • [8] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
  • [9] CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M. Hoskins
    Lisa A. Carey
    Howard L. McLeod
    Nature Reviews Cancer, 2009, 9 : 576 - 586
  • [10] Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    Carmen W. H. Chan
    Bernard M. H. Law
    Winnie K. W. So
    Ka Ming Chow
    Mary M. Y. Waye
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1395 - 1404
12345